New cancer Drug's dosing secrets explored in healthy volunteers
NCT ID NCT06385119
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study in 28 healthy adults looks at how food and the drug cobicistat change the way plixorafenib (FORE8394) is processed by the body. Participants take single doses under different conditions—fasted, with low-fat or high-fat meals, and with or without cobicistat. The goal is to find the best way to give plixorafenib in future studies, while checking for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Plixorafenib (also known as FORE8394) and cobicistat (Tybost)
What this could lead to
If successful, this study will help determine the right dosing conditions for plixorafenib in future trials, potentially leading to better treatment options for certain cancers.
What could go wrong
This is an early Phase 1 study in only 28 healthy people, not patients. It tests drug levels and safety, not whether plixorafenib works against any disease. Results may not predict effects in sick patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PPD - Austin Research Unit
Austin, Texas, 78744, United States